Terms of the settlement, which revolve around US Patent No. 6,054,270, allow BioDiscovery to continue selling its full line of microarray-image and data-analysis software, but does not give it a license to any OGT patents.
BioDiscovery's software "may not be used to make any oligonucleotide arrays coming within the scope of any OGT patent or analyze polynucleotides using oligonucleotide arrays coming within the scope of any OGT patent or according to any method claimed in any OGT Patent, unless the user has a license from OGT or uses arrays made by licensees of OGT," the companies said.